The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma

Lung Cancer

Volumn 73, Issue 1, 2011, Pages 45-50

  Kozu, Yoshiki ^a,c   Tsuta, Koji ^a   Kohno, Takashi ^b   Sekine, Ikuo ^a   Yoshida, Akihiko ^a,d   Watanabe, Shunichi ^a   Tamura, Tomohide ^a   Yokota, Jun ^b   Suzuki, Kenji ^c   Asamura, Hisao ^a   Furuta, Koh ^a   Tsuda, Hitoshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Epidermal growth factor receptor; High specificity; Immunohistochemistry; Lung adenocarcinoma; Mutation; Mutation specific antibody; Tyrosine kinase inhibitor

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EXON; FEMALE; GENE DELETION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODY SPECIFICITY; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POINT MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION;

EID: 79957676308     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.11.003     Document Type: Article

References (36)

1. Dibb N.J., Dilworth S.M., Mol C.D. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 2004, 4:718-727.
2. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
3. Kantarjian H.M., Larson R.A., Guilhot F., O'Brien S.G., Mone M., Rudoltz M., et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009, 115:551-560.
4. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
5. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
6. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
7. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002, 62:5749-5754.
8. Mitsudomi T., Kosaka T., Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 2006, 11:190-198.
9. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21:2237-2246.
10. Han S.W., Kim T.Y., Hwang P.G., Jeong S., Kim J., Choi I.S., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005, 23:2493-2501.
11. Kim K.S., Jeong J.Y., Kim Y.C., Na K.J., Kim Y.H., Ahn S.J., et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 2005, 11:2244-2251.
12. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520.
13. Mitsudomi T., Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007, 98:1817-1824.
14. Riely G.J., Politi K.A., Miller V.A., Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006, 12:7232-7241.
15. Fukui T., Ohe Y., Tsuta K., Furuta K., Sakamoto H., Takano T., et al. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res 2008, 14:4751-4757.
16. Pao W., Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007, 13:4954-4955.
17. Endoh H., Ishibashi Y., Yamaki E., Yoshida T., Yajima T., Kimura H., et al. Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. Lung Cancer 2009, 63:241-246.
18. Hijiya N., Miyawaki M., Kawahara K., Akamine S., Tsuji K., Kadota J., et al. Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. Hum Pathol 2008, 39:316-323.
19. Yu J., Kane S., Wu J., Benedettini E., Li D., Reeves C., et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15:3023-3028.
20. Brevet M., Arcila M., Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010, 12:169-176.
21. Li D., Chen S., Hu C., Lei Y., Yu J. Immunohistochemistry with mutation specific antibodies detecting the status of EGFR mutations in non-small-cell lung cancer. Mod Pathol 2010, 23:407A.
22. Kato Y., Peled N., Wynes M.W., Yoshida K., Pardo M., Mascaux C., et al. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 2010, 5:1551-1558.
23. Kawahara A., Yamamoto C., Nakashima K., Azuma K., Hattori S., Kashihara M., et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 2010, 16:3163-3170.
24. Kitamura A., Hosoda W., Sasaki E., Mitsudomi T., Yatabe Y. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 2010, 16:3349-3355.
25. Beasley M.B., Brambilla E., Travis W.D. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005, 40:90-97.
26. Green S., Weiss G.R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992, 10:239-253.
27. Nomoto K., Tsuta K., Takano T., Fukui T., Yokozawa K., Sakamoto H., et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 2006, 126:608-615.
28. Takano T., Ohe Y., Tsuta K., Fukui T., Sakamoto H., Yoshida T., et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced nonsmall cell lung cancer treated with gefitinib. Clin Cancer Res 2007, 13:5385-5390.
29. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23:6829-6837.
30. Srinivasan M., Sedmak D., Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002, 161:1961-1971.
31. Jiang S.X., Yamashita K., Yamamoto M., Piao C.J., Umezawa A., Saegusa M., et al. EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. Int J Cancer 2008, 123:2480-2486.
32. Nagai Y., Miyazawa H., Huqun, Tanaka T., Udagawa K., Kato M., et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005, 65:7276-7282.
33. Sakurada A., Lara-Guerra H., Liu N., Shepherd F.A., Tsao M.S. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol 2008, 3:527-529.
34. Dziadziuszko R., Hirsch F.R., Varella-Garcia M., Bunn P.A. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization-why, when, and how?. Clin Cancer Res 2006, 12:4409s-4415s.
35. Jacobs T.W., Gown A.M., Yaziji H., Barnes M.J., Schnitt S.J. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999, 17:1983-1987.
36. McCormick S.R., Lillemoe T.J., Beneke J., Schrauth J., Reinartz J. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol 2002, 117:935-943.